YABAO PHARM.CORP: Sitagliptin Metformin Extended-Release Tablets have obtained the drug registration certificate
YABAO PHARM.CORP announced that its wholly-owned subsidiary Beijing YABAO Biopharmaceutical Co., Ltd. has obtained the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets issued by the National Medical Products Administration. This medication is suitable for adult patients with type 2 diabetes, used in combination with Sitagliptin and Metformin. Sitagliptin Metformin Extended-Release Tablets were developed by MERCK SHARP DOHME and were approved for sale in the United States in 2012 under the brand name JANUMETXR®. It is expected that the sales of this drug in the domestic market will reach 921 million yuan in 2024
According to the Zhitong Finance APP, YABAO PHARM.CORP (600351.SH) announced that its wholly-owned subsidiary Beijing Yabao Biopharmaceutical Co., Ltd. (hereinafter referred to as "Yabao Biopharmaceutical") has received the Drug Registration Certificate for Sitagliptin Metformin Sustained-Release Tablets (Certificate No.: 2025S03027) approved and issued by the National Medical Products Administration (hereinafter referred to as "NMPA").
Sitagliptin Metformin Sustained-Release Tablets are suitable for adult patients with type 2 diabetes who are receiving combined treatment with Sitagliptin and Metformin Sustained-Release Tablets. Sitagliptin Metformin Sustained-Release Tablets were developed by MERCK SHARP DOHME and were approved for marketing in the United States in 2012 under the brand name JANUMETXR®. According to data from the China Pharmaceutical Market, the sales amount of Sitagliptin Metformin Tablets (I), Sitagliptin Metformin Tablets (II), and Sitagliptin Metformin Sustained-Release Tablets in China is approximately RMB 921 million in 2024, of which the sales amount in public hospitals is RMB 721 million, and the sales amount in retail pharmacies is RMB 200 million
